Literature DB >> 22290745

Incidence rates of endometrial hyperplasia, endometrial cancer and hysterectomy from 1980 to 2003 within a large prepaid health plan.

James V Lacey1, Victoria M Chia, Brenda B Rush, Danny J Carreon, Douglas A Richesson, Olga B Ioffe, Brigitte M Ronnett, Nilanjan Chatterjee, Bryan Langholz, Mark E Sherman, Andrew G Glass.   

Abstract

Obesity strongly increases the risk of endometrial cancer and is projected to increase current and future endometrial cancer incidence. In order to fully understand endometrial cancer incidence, one should also examine both hysterectomy, which eliminates future risk of endometrial cancer, and endometrial hyperplasia (EH), a precursor that prompts treatment (including hysterectomy). Hysterectomy and EH are more common than endometrial cancer, but data on simultaneous temporal trends of EH, hysterectomy and endometrial cancer are lacking. We used linked pathology, tumor registry, surgery and administrative datasets at the Kaiser Permanente Northwest Health Plan to calculate age-adjusted and age-specific rates, 1980-2003, of EH only (N = 5,990), EH plus hysterectomy (N = 904), hysterectomy without a diagnosis of EH or cancer (N = 14,926) and endometrial cancer (N = 1,208). Joinpoint regression identified inflection points and quantified annual percentage changes (APCs). The EH APCs were -5.3% (95% confidence interval [CI] = -7.4% to -3.2%) for 1980-1990, -12.9% (95% CI = -15.6% to -10.1%) for 1990-1999 and 2.4% (95% CI = -6.6% to 12.2%) for 1999-2003. The EH-plus-hysterectomy APCs were -8.6% (95% CI = -10.6% to -6.5%) for 1980-2000 and 24.5% (95% CI = -16.5% to 85.7%) for 2000-2003. Hysterectomy rates did not significantly change over time. The endometrial cancer APCs were -6.5% (95% CI = -10.3% to -2.6%) for 1980-1988 and 1.4% (95% CI = -0.2% to 3.0%) for 1988-2003. Hysterectomy rates were unchanged, but increased endometrial cancer incidence after 1988 and the reversal, in 1999, of the longstanding decline in EH incidence could reflect the influence of obesity on endometrial neoplasia.
Copyright © 2012 UICC.

Entities:  

Mesh:

Year:  2012        PMID: 22290745     DOI: 10.1002/ijc.27457

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

1.  Functional characterization of recurrent FOXA2 mutations seen in endometrial cancers.

Authors:  Robert Neff; Craig M Rush; Blair Smith; Floor J Backes; David E Cohn; Paul J Goodfellow
Journal:  Int J Cancer       Date:  2018-09-29       Impact factor: 7.396

2.  Menstrual Cycle Hormone Changes in Women Traversing Menopause: Study of Women's Health Across the Nation.

Authors:  Nanette Santoro; Sybil L Crawford; Samar R El Khoudary; Amanda A Allshouse; Sherri-Ann Burnett-Bowie; Joel Finkelstein; Carol Derby; Karen Matthews; Howard M Kravitz; Sioban D Harlow; Gail A Greendale; Ellen B Gold; Rasa Kazlauskaite; Dan McConnell; Genevieve Neal-Perry; Jelena Pavlovic; John Randolph; Gerson Weiss; Hsiang-Yu Chen; Bill Lasley
Journal:  J Clin Endocrinol Metab       Date:  2017-07-01       Impact factor: 5.958

3.  Menstrual and Reproductive Factors, Hormone Use, and Risk of Pancreatic Cancer: Analysis From the International Pancreatic Cancer Case-Control Consortium (PanC4).

Authors:  Leila Lujan-Barroso; Wei Zhang; Sara H Olson; Yu-Tang Gao; Herbert Yu; Peter A Baghurst; Paige M Bracci; H Bas Bueno-de-Mesquita; Lenka Foretová; Steven Gallinger; Ivana Holcatova; Vladimír Janout; Bu-Tian Ji; Robert C Kurtz; Carlo La Vecchia; Pagona Lagiou; Donghui Li; Anthony B Miller; Diego Serraino; Witold Zatonski; Harvey A Risch; Eric J Duell
Journal:  Pancreas       Date:  2016-11       Impact factor: 3.327

4.  Cancer incidence trends among Asian American populations in the United States, 1990-2008.

Authors:  Scarlett Lin Gomez; Anne-Michelle Noone; Daphne Y Lichtensztajn; Steve Scoppa; James T Gibson; Lihua Liu; Cyllene Morris; Sandy Kwong; Kari Fish; Lynne R Wilkens; Marc T Goodman; Dennis Deapen; Barry A Miller
Journal:  J Natl Cancer Inst       Date:  2013-07-22       Impact factor: 13.506

5.  An epidemiological model for prediction of endometrial cancer risk in Europe.

Authors:  Anika Hüsing; Laure Dossus; Pietro Ferrari; Anne Tjønneland; Louise Hansen; Guy Fagherazzi; Laura Baglietto; Helena Schock; Jenny Chang-Claude; Heiner Boeing; Annika Steffen; Antonia Trichopoulou; Christina Bamia; Michalis Katsoulis; Vittorio Krogh; Domenico Palli; Salvatore Panico; N Charlotte Onland-Moret; Petra H Peeters; H Bas Bueno-de-Mesquita; Elisabete Weiderpass; Inger T Gram; Eva Ardanaz; Mireia Obón-Santacana; Carmen Navarro; Emilio Sánchez-Cantalejo; Nerea Etxezarreta; Naomi E Allen; Kay Tee Khaw; Nick Wareham; Sabina Rinaldi; Isabelle Romieu; Melissa A Merritt; Marc Gunter; Elio Riboli; Rudolf Kaaks
Journal:  Eur J Epidemiol       Date:  2015-05-13       Impact factor: 8.082

6.  The incidence rates of endometrial hyperplasia and endometrial cancer: a four-year population-based study.

Authors:  Jin-Sung Yuk
Journal:  PeerJ       Date:  2016-08-24       Impact factor: 2.984

Review 7.  New classification system of endometrial hyperplasia WHO 2014 and its clinical implications.

Authors:  Katarzyna Sobczuk; Anna Sobczuk
Journal:  Prz Menopauzalny       Date:  2017-10-12

8.  Effectiveness of Megestrol for the Treatment of Patients with Atypical Endometrial Hyperplasia or Endometrial Endometrioid Adenocarcinoma (Stage IA, Well Differentiated).

Authors:  Setareh Akhavan; Fahimeh Sabet; Azam-Sadat Mousavi; Mitra Modarres Gilani; Shahrzad Sheikh Hasani
Journal:  J Res Pharm Pract       Date:  2021-12-25

9.  Hormonal Receptor Expression in Endometrial Carcinoma: A Retrospective Immunohistochemical Study in a Nigerian Tertiary Hospital.

Authors:  Segun Samson Odetola; Mustapha Akanji Ajani; Oluwadamilare Iyapo; Ayodeji A Salami; Clement Abu Okolo
Journal:  J West Afr Coll Surg       Date:  2022-03-26

10.  The value of MRI in management of endometrial hyperplasia with atypia.

Authors:  Purushothaman Natarajan; Angela Vinturache; Richard Hutson; David Nugent; Timothy Broadhead
Journal:  World J Surg Oncol       Date:  2020-02-10       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.